GELMETIX
Gelmetix develops multiple grades of polymer gel to provide affordable non-invasive alternatives to surgery for conditions like Chronic Lower Back pain and Osteoarthritis. Their lead product is a hydrogel for nucleus pulposus augmentation to relieve pain in patients suffering from Chronic Low Back Pain. Gelmetix is a diversified therapeutic biomaterials company incorporated in the UK. It has offices in London, Paris, and Manchester.
GELMETIX
Social Links:
Industry:
Biotechnology Commercial Health Care Medical Medical Device
Founded:
2012-01-01
Address:
Macclesfield, Cheshire East, United Kingdom
Country:
United Kingdom
Website Url:
http://www.gelmetix.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
12.05 M GBP
Technology used in webpage:
SPF Domain Not Resolving Amazon GoDaddy DNS AWS Global Accelerator GoDaddy Email
Similar Organizations
ATRO Medical
Medical technology company developing a polymer meniscus implant.
CeQur
CeQur develops and commercializes insulin delivery systems, giving people with type 2 diabetes freedom from multiple daily injections.
Vero Biotech
Vero Biotech is a biopharmaceutical company developing products to address the medical needs of patients with pulmonary, cardiac diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Wealth Club
Wealth Club investment in Series C - Gelmetix
Jonathan Milner
Jonathan Milner investment in Series C - Gelmetix
Seneca Partners
Seneca Partners investment in Series C - Gelmetix
University of Manchester
University of Manchester investment in Series B - Gelmetix
Jonathan Milner
Jonathan Milner investment in Series B - Gelmetix
Seneca Partners
Seneca Partners investment in Series B - Gelmetix
SyndicateRoom
SyndicateRoom investment in Series B - Gelmetix
The North West Fund
The North West Fund investment in Series A - Gelmetix
University of Manchester
University of Manchester investment in Venture Round - Gelmetix
The North West Fund
The North West Fund investment in Venture Round - Gelmetix
Official Site Inspections
http://www.gelmetix.com Semrush global rank: 7.7 M Semrush visits lastest month: 446
- Host name: 8.128.153.160.host.secureserver.net
- IP address: 160.153.128.8
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Gelmetix" on Search Engine
Gelmetix – Transforming Individuals' Lives
A platform for development. Gelmetix’s patented polymer technology provides a platform for tackling pain and restoring movement for chronic low-back pain, and in joints throughout the body. Our gels also offer the potential to act as a carrier, allowing the introduction of regenerative agents.See details»
About – Gelmetix
Leadership team. Andy Weymann MD. Chief Executive Officer & Director of the Board. Cristin Taylor. Senior Vice President Clinical and Medical Affairs. Michelle Lee. Senior Vice President Process and Compliance. Nana Owusu …See details»
Gelmetix | LinkedIn
Gelmetix | 821 followers on LinkedIn. We focus on the treatment of chronic lower back pain caused by the degeneration of intervertebral discs | Back pain is debilitating and limiting. It forces...See details»
Clinical Trial – Gelmetix
Clinical trial. Patient information. At Gelmetix, we are undertaking the first-in-human trial for DXM, which we hope to develop as a means of relieving pain and providing other benefits to patients suffering from early-stage discogenic chronic lower back pain.See details»
Gelmetix Company Profile: Valuation, Funding & Investors
Pharmaceuticals. Corporate Office. Alderley Park. Nether Alderley. SK10 4TG. England, United Kingdom. . Gelmetix Timeline. 2021 2022 2023 2024. Financing Round. Want detailed data on 3M+ companies?See details»
Gelmetix closes successful £5 million capital raise, progresses to ...
May 11, 2021 About. Founded in 2012 at University of Manchester, Gelmetix is a UK medtech company focused on treating chronic lower back pain caused by the degeneration of the intervertebral discs. Gelmetix’s polymer gel technology also has the potential to be adapted and extended for other uses.See details»
ABOUT MANCHESTER: University of Manchester spin-out Gelmetix …
Nov 20, 2018 ABOUT MANCHESTER: University of Manchester spin-out Gelmetix raises £1.2m to develop back pain treatment Anthony Freemont, BSc, MD, FRCP, FRCPath Division of Cell Matrix Biology & Regenerative Medicine (L5)See details»
Gelmetix Company Profile - Craft
Private. Status. Active. Founded. 2012. HQ. Alderley Edge, GB | view all locations. Website. https://www.gelmetix.com/ Cybersecurity rating. Sectors. Healthcare. bioengineering. biotech. pharma. Key People. Philippe Jenny, Chief Executive Officer, Director. Sam Bakri, Vice Chairman, and Co-founder. Oliver Schofield, Chief Financial Officer.See details»
Manchester university medtech firm raises £1.2m to develop back …
Nov 9, 2018 Dr Philippe Jenny. University of Manchester spin-out company Gelmetix has secured £1.2 funding to help develop its non-surgical treatment for chronic lower back pain. The company has created a...See details»
Gelmetix - Crunchbase Company Profile & Funding
Details. Industries. Biotechnology. Commercial. Health Care. Medical Device. Headquarters Regions Europe, Middle East, and Africa (EMEA) Founded Date 2012. Founders Brian R Saunders, Philippe Jenny, Tony Freemont. Operating Status Active. Last Funding Type Series C. Also Known As Gelexir Healthcare. Company Type For Profit.See details»
Gelexir Healthcare Ltd rebrands and becomes Gelmetix
Nov 1, 2018 Gelmetix is a medical device company developing multiple grades of polymer gel to provide affordable non-invasive alternatives to surgery for conditions like chronic lower back pain and osteoarthritis.See details»
Gelexir becomes Gelmetix – Gelmetix
Jul 1, 2018 Gelexir Healthcare announces rebranding and becomes ‘Gelmetix’, in line with its new multi-product strategy.See details»
Stemmatters and Gelmetix sign co-development agreement
Oct 19, 2018 News & Events. Stemmatters and Gelmetix sign co-development agreement. previous. next. (Guimarães, Portugal and Manchester, United Kingdom - October 19, 2018) Stemmatters and Gelmetix have established an agreement to develop an innovative hydrogel based device for the treatment of cartilage lesions.See details»
Gelmetix - Funding, Financials, Valuation & Investors - Crunchbase
Gelmetix has raised a total of. £10.3M. in funding over 4 rounds. Their latest funding was raised on May 14, 2021 from a Series C round. Gelmetix is funded by 6 investors. Wealth Club and Jonathan Milner are the most recent investors. Unlock for free.See details»
Gelmetix - Contacts, Employees, Board Members, Advisors
Organization. Gelmetix. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Employee Profiles 6. Number of Board Member and Advisor Profiles 4. Contacts 4. About. Gelmetix has 6 current employee profiles, including Director and Chief Innovation Officer Philippe Jenny.See details»
Stemmatters and Gelmetix sign collaboration agreement for ... - P …
About Gelmetix. Gelmetix Limited (Manchester, United Kingdom) is medical device manufacturer, originated from the University of Manchester As a therapeutic biomaterial company, Gelmetix designs novel gel based approaches to a variety of debilitating orthopaedic conditions.See details»
Gelmetix | VentureRadar
Gelmetix develops multiple grades of polymer gel to provide affordable non-invasive alternatives to surgery for conditions like chronic lower back pain and osteoarthritis. Our goal is to become a diversified solution-platform and to subsequently develop and in-license different families of products.See details»
News – Gelmetix
Dec 1, 2017 Gelmetix signs collaboration for development of Knee Osteoarthritis product. Gelmetix and Stemmatters, a Portuguese company, sign collaboration agreement for development of innovative cartilage repair device for Knee Ostearthritis. 19 October 2018. Gelexir becomes Gelmetix.See details»
Gelmetix — Sedley Place
Gelmetix’s ambition is to transform individual’s lives through early-stage, minimally-invasive, effective and affordable solutions to either chronic pain or poor body functioning. It’s in the process of developing a multi-product portfolio of gel-based, therapeutic biomaterial medical devices, and e.See details»
Investors – Gelmetix
We are a UK-based medtech company whose mission is to free the world from the burden of chronic pain and to free individuals to move and live without pain. Back pain is a major public health problem, accounting for the highest number of disability-adjusted life years compared to any other condition or disease globally.See details»